Hologic, Inc. (NASDAQ:HOLX) Shares Bought by Signaturefd LLC

Signaturefd LLC raised its holdings in Hologic, Inc. (NASDAQ:HOLX) by 34.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,940 shares of the medical equipment provider’s stock after buying an additional 754 shares during the period. Signaturefd LLC’s holdings in Hologic were worth $212,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. State Street Corp increased its position in shares of Hologic by 0.8% during the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock worth $847,944,000 after purchasing an additional 81,057 shares in the last quarter. FMR LLC increased its position in shares of Hologic by 64.0% during the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after purchasing an additional 2,174,093 shares in the last quarter. Victory Capital Management Inc. increased its position in shares of Hologic by 0.5% during the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider’s stock worth $354,506,000 after purchasing an additional 24,358 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Hologic by 0.7% during the third quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock worth $208,051,000 after purchasing an additional 18,774 shares in the last quarter. Finally, Nordea Investment Management AB increased its position in shares of Hologic by 32.7% during the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after purchasing an additional 544,889 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

HOLX has been the topic of a number of research analyst reports. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Morgan Stanley cut their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Wolfe Research assumed coverage on Hologic in a report on Friday, December 13th. They set a “peer perform” rating on the stock. Royal Bank of Canada lowered their price target on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a report on Thursday, February 6th. Finally, Stephens reissued an “overweight” rating and set a $84.00 price target on shares of Hologic in a report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $84.62.

Hologic Price Performance

Shares of HOLX opened at $61.47 on Friday. Hologic, Inc. has a twelve month low of $60.34 and a twelve month high of $84.67. The stock’s 50 day moving average is $66.06 and its two-hundred day moving average is $73.99. The firm has a market capitalization of $13.79 billion, a PE ratio of 19.39, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.